Stanford scientists have developed species cross-reactive B7H3-targeting CAR-T cells that can effectively target both human and mouse tumors, enabling more accurate preclinical testing in immunocompetent models.
Stanford researchers in the Cochran Lab have patented a potential pancreatic cancer therapeutic approach using novel agents that bind tightly to and inhibit a cancer factor called LIF (leukemia inhibitory factor).
Researchers at Stanford, led by Prof. Crystal Mackall and Prof. Jennifer R Cochran, have developed a unique approach to cancer treatment by tackling both the innate and adaptive immune systems.